Answer
Yes, regorafenib (Stivarga) has been associated with an increased incidence of infections, some fatal, and treatment interruption should be considered if infections worsen.
Sources for this answer
- Stivarga 40 mg film coated tabletsBayer plc · emc · SmPC §4.4 Special warnings and precautions for use · Version 7Document updated
Sources checked